Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 22 | 2026 | 743 | 6.150 |
Why?
|
| Adenocarcinoma | 8 | 2023 | 987 | 2.300 |
Why?
|
| Colorectal Neoplasms | 6 | 2026 | 635 | 1.790 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2022 | 189 | 1.330 |
Why?
|
| Emergency Service, Hospital | 4 | 2026 | 1212 | 1.200 |
Why?
|
| Quality Indicators, Health Care | 2 | 2026 | 234 | 1.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 300 | 0.830 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1422 | 0.730 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 418 | 0.710 |
Why?
|
| Barrett Esophagus | 3 | 2014 | 361 | 0.690 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2020 | 6 | 0.650 |
Why?
|
| Ileitis | 1 | 2020 | 10 | 0.650 |
Why?
|
| Diabetes Mellitus | 3 | 2024 | 895 | 0.610 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 87 | 0.580 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 505 | 0.560 |
Why?
|
| United States | 11 | 2026 | 11834 | 0.540 |
Why?
|
| Veterans | 3 | 2024 | 1792 | 0.540 |
Why?
|
| Colonic Polyps | 1 | 2019 | 85 | 0.540 |
Why?
|
| Aged | 21 | 2026 | 20958 | 0.530 |
Why?
|
| Risk Factors | 14 | 2024 | 11003 | 0.510 |
Why?
|
| Crohn Disease | 1 | 2020 | 291 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2018 | 748 | 0.490 |
Why?
|
| Aspirin | 1 | 2017 | 216 | 0.480 |
Why?
|
| Middle Aged | 22 | 2026 | 28499 | 0.470 |
Why?
|
| Humans | 40 | 2026 | 130776 | 0.450 |
Why?
|
| Proportional Hazards Models | 6 | 2023 | 1408 | 0.450 |
Why?
|
| Coffee | 1 | 2015 | 30 | 0.440 |
Why?
|
| Caffeine | 1 | 2015 | 67 | 0.440 |
Why?
|
| Gastric Balloon | 1 | 2014 | 2 | 0.420 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2014 | 14 | 0.420 |
Why?
|
| Air | 1 | 2014 | 21 | 0.410 |
Why?
|
| Mesenteric Ischemia | 1 | 2014 | 30 | 0.410 |
Why?
|
| Portal Vein | 1 | 2014 | 88 | 0.400 |
Why?
|
| Device Removal | 1 | 2014 | 224 | 0.360 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 92 | 0.350 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2012 | 72 | 0.350 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 366 | 0.330 |
Why?
|
| Male | 22 | 2026 | 64680 | 0.310 |
Why?
|
| Feeding Behavior | 1 | 2015 | 717 | 0.300 |
Why?
|
| Body Composition | 2 | 2023 | 548 | 0.290 |
Why?
|
| Prevalence | 3 | 2024 | 2684 | 0.280 |
Why?
|
| Female | 19 | 2026 | 70630 | 0.270 |
Why?
|
| Incidence | 4 | 2020 | 3349 | 0.270 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 909 | 0.270 |
Why?
|
| Mass Screening | 3 | 2022 | 808 | 0.270 |
Why?
|
| Endoscopy, Digestive System | 3 | 2019 | 153 | 0.260 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2024 | 718 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 1005 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3418 | 0.220 |
Why?
|
| Prospective Studies | 7 | 2021 | 6494 | 0.220 |
Why?
|
| Gastroenterologists | 1 | 2023 | 14 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2017 | 3716 | 0.180 |
Why?
|
| Survival Analysis | 4 | 2019 | 1512 | 0.180 |
Why?
|
| Cyst Fluid | 1 | 2021 | 6 | 0.180 |
Why?
|
| Adult | 10 | 2020 | 31269 | 0.180 |
Why?
|
| Pancreatic Cyst | 1 | 2021 | 29 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2022 | 97 | 0.170 |
Why?
|
| Pancreas | 1 | 2022 | 227 | 0.160 |
Why?
|
| Logistic Models | 2 | 2023 | 1824 | 0.160 |
Why?
|
| Adipose Tissue | 2 | 2023 | 494 | 0.160 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 280 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2104 | 0.160 |
Why?
|
| Survival Rate | 3 | 2020 | 2145 | 0.160 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 49 | 0.160 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 373 | 0.150 |
Why?
|
| Duodenal Diseases | 1 | 2019 | 28 | 0.150 |
Why?
|
| Proteome | 1 | 2021 | 287 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2019 | 361 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 80 | 0.150 |
Why?
|
| Jews | 1 | 2019 | 34 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 199 | 0.150 |
Why?
|
| Adenoma | 1 | 2020 | 145 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 2956 | 0.150 |
Why?
|
| Syphilis | 1 | 2019 | 95 | 0.140 |
Why?
|
| Penicillins | 1 | 2019 | 154 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2019 | 109 | 0.140 |
Why?
|
| Leukocytes | 1 | 2019 | 207 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6784 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2020 | 288 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 93 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 277 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 681 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 579 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2017 | 1231 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17674 | 0.130 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 1000 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1388 | 0.130 |
Why?
|
| Nurses | 1 | 2017 | 75 | 0.130 |
Why?
|
| Health Surveys | 1 | 2017 | 260 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 164 | 0.120 |
Why?
|
| Weight Loss | 1 | 2020 | 526 | 0.120 |
Why?
|
| Colonoscopy | 2 | 2020 | 246 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 731 | 0.120 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 69 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5230 | 0.120 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 138 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2020 | 1685 | 0.110 |
Why?
|
| Paris | 1 | 2015 | 12 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2019 | 381 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3417 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 592 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2020 | 5089 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 673 | 0.100 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 44 | 0.100 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2013 | 20 | 0.100 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 1358 | 0.100 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 1302 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 4934 | 0.100 |
Why?
|
| Registries | 1 | 2020 | 1599 | 0.100 |
Why?
|
| Smoking | 1 | 2018 | 926 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 154 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 231 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2019 | 1086 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 385 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2014 | 251 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1272 | 0.080 |
Why?
|
| Age of Onset | 1 | 2012 | 597 | 0.080 |
Why?
|
| Family | 1 | 2014 | 586 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 556 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 265 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3062 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 6241 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2018 | 147 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3823 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 904 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1387 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 6145 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 99 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 98 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 297 | 0.050 |
Why?
|
| Cachexia | 1 | 2023 | 57 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 916 | 0.050 |
Why?
|
| Muscular Atrophy | 1 | 2023 | 83 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 216 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 828 | 0.040 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 7 | 0.040 |
Why?
|
| Treponema pallidum | 1 | 2019 | 48 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2019 | 125 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12910 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 736 | 0.030 |
Why?
|
| Telomere | 1 | 2019 | 219 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2024 | 785 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2017 | 55 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 141 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 137 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 105 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 426 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 788 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1241 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1502 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1896 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1490 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 2013 | 35 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 230 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1802 | 0.020 |
Why?
|
| Child | 1 | 2012 | 26214 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1843 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2020 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1609 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2307 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 2648 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 2389 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3869 | 0.010 |
Why?
|